Lumos Diagnostics Holdings Ltd (LDX) - Net Assets
Based on the latest financial reports, Lumos Diagnostics Holdings Ltd (LDX) has net assets worth AU$6.16 Million AUD as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$20.81 Million) and total liabilities (AU$14.65 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$6.16 Million |
| % of Total Assets | 29.58% |
| Annual Growth Rate | 10.92% |
| 5-Year Change | -89.44% |
| 10-Year Change | N/A |
| Growth Volatility | 122.84 |
Lumos Diagnostics Holdings Ltd - Net Assets Trend (2017–2024)
This chart illustrates how Lumos Diagnostics Holdings Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Lumos Diagnostics Holdings Ltd (2017–2024)
The table below shows the annual net assets of Lumos Diagnostics Holdings Ltd from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | AU$6.16 Million | -13.39% |
| 2023-12-31 | AU$7.11 Million | -25.15% |
| 2022-12-31 | AU$9.50 Million | -46.89% |
| 2021-12-31 | AU$17.89 Million | -69.31% |
| 2020-12-31 | AU$58.28 Million | +163.05% |
| 2019-12-31 | AU$22.16 Million | +90.02% |
| 2018-12-31 | AU$11.66 Million | +291.20% |
| 2017-12-31 | AU$2.98 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Lumos Diagnostics Holdings Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9780846429.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$103.96 Million | 1688.53% |
| Other Comprehensive Income | AU$35.00K | 0.57% |
| Total Equity | AU$6.16 Million | 100.00% |
Lumos Diagnostics Holdings Ltd Competitors by Market Cap
The table below lists competitors of Lumos Diagnostics Holdings Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jeld-Wen Holding Inc
NYSE:JELD
|
$109.35 Million |
|
Martin Midstream Partners LP
NASDAQ:MMLP
|
$109.35 Million |
|
Bioxyne Ltd
AU:BXN
|
$109.36 Million |
|
Majestic Gold Corp.
V:MJS
|
$109.37 Million |
|
Netanel Menivim Ltd.
TA:NTNB
|
$109.33 Million |
|
Bulten AB
ST:BULTEN
|
$109.32 Million |
|
TOPMATERIAL LTD
KQ:360070
|
$109.32 Million |
|
Turbogen Chp
TA:TURB
|
$109.30 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Lumos Diagnostics Holdings Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 7,109,000 to 6,157,000, a change of -952,000 (-13.4%).
- Net loss of 7,183,000 reduced equity.
- Share repurchases of 6,222,000 reduced equity.
- New share issuances of 6,222,000 increased equity.
- Other comprehensive income increased equity by 294,000.
- Other factors increased equity by 5,937,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-7.18 Million | -116.66% |
| Share Repurchases | AU$6.22 Million | -101.06% |
| Share Issuances | AU$6.22 Million | +101.06% |
| Other Comprehensive Income | AU$294.00K | +4.78% |
| Other Changes | AU$5.94 Million | +96.43% |
| Total Change | AU$- | -13.39% |
Book Value vs Market Value Analysis
This analysis compares Lumos Diagnostics Holdings Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 21.54x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 1.10x to 21.54x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | AU$0.18 | AU$0.20 | x |
| 2018-12-31 | AU$0.69 | AU$0.20 | x |
| 2019-12-31 | AU$1.00 | AU$0.20 | x |
| 2020-12-31 | AU$0.39 | AU$0.20 | x |
| 2021-12-31 | AU$0.12 | AU$0.20 | x |
| 2022-12-31 | AU$0.04 | AU$0.20 | x |
| 2023-12-31 | AU$0.01 | AU$0.20 | x |
| 2024-12-31 | AU$0.01 | AU$0.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Lumos Diagnostics Holdings Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -116.66%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -57.46%
- • Asset Turnover: 0.60x
- • Equity Multiplier: 3.38x
- Recent ROE (-116.66%) is below the historical average (-92.15%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -42.49% | -65.98% | 0.22x | 2.98x | AU$-1.56 Million |
| 2018 | -39.41% | -102.57% | 0.18x | 2.18x | AU$-5.76 Million |
| 2019 | -41.89% | -160.16% | 0.19x | 1.37x | AU$-11.50 Million |
| 2020 | -25.79% | -79.72% | 0.19x | 1.68x | AU$-20.86 Million |
| 2021 | -255.66% | -393.16% | 0.31x | 2.07x | AU$-47.51 Million |
| 2022 | -94.45% | -85.15% | 0.41x | 2.68x | AU$-9.92 Million |
| 2023 | -120.86% | -77.19% | 0.41x | 3.78x | AU$-9.30 Million |
| 2024 | -116.66% | -57.46% | 0.60x | 3.38x | AU$-7.80 Million |
Industry Comparison
This section compares Lumos Diagnostics Holdings Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $44,088,039
- Average return on equity (ROE) among peers: -1111.09%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Lumos Diagnostics Holdings Ltd (LDX) | AU$6.16 Million | -42.49% | 2.38x | $109.34 Million |
| 4DMEDICAL Ltd (4DX) | $64.24 Million | -46.81% | 0.48x | $2.37 Billion |
| Adherium Ltd (ADR) | $14.04 Million | -107.13% | 0.21x | $7.37 Million |
| Aroa Biosurgery Ltd (ARX) | $1.81 Million | 0.00% | 6.66x | $128.82 Million |
| Atomo Diagnostics Ltd (AT1) | $47.82K | -10766.62% | 247.20x | $16.05 Million |
| Anteris Technologies Global Corp (AVR) | $13.64 Million | -10.42% | 0.08x | $582.48 Million |
| Control Bionics Ltd (CBL) | $7.12 Million | -79.13% | 0.22x | $18.36 Million |
| Cardiex Ltd (CDX) | $7.91 Million | -70.11% | 0.42x | $13.23 Million |
| Compumedics Ltd (CMP) | $6.91 Million | 1.78% | 1.78x | $39.58 Million |
| Cochlear Ltd (COH) | $319.34 Million | 36.08% | 0.90x | $7.80 Billion |
| Cleo Diagnostics Ltd (COV) | $5.83 Million | -68.54% | 0.19x | $58.10 Million |
About Lumos Diagnostics Holdings Ltd
Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company's products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, … Read more